×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PRLD – prelude therapeutics incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PRLD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
06:30 am
prld
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Low
Report
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
4/20
06:17 am
prld
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 [Yahoo! Finance]
Low
Report
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 [Yahoo! Finance]
4/20
06:00 am
prld
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Low
Report
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
4/15
07:30 am
prld
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
High
Report
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
3/17
05:14 pm
prld
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting [Yahoo! Finance]
3/17
04:31 pm
prld
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Medium
Report
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
3/11
08:03 am
prld
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
Medium
Report
Prelude Therapeutics (PRLD) had its price target raised by Citizens Jmp from $3.00 to $6.00. They now have a "market outperform" rating on the stock.
3/10
07:37 am
prld
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
High
Report
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
3/10/2026
07:01 am
PRLD
prelude therapeutics incorporated
MISS
Report
15.4%
prelude therapeutics incorporated
11/12/2025
07:01 am
PRLD
prelude therapeutics incorporated
BEAT
Report
5.8%
prelude therapeutics incorporated
8/14/2025
07:00 am
PRLD
prelude therapeutics incorporated
BEAT
Report
2.7%
prelude therapeutics incorporated
5/6/2025
04:05 pm
PRLD
prelude therapeutics incorporated
BEAT
Report
-4.0%
prelude therapeutics incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/20
06:17 am
prld
Form 8-K Prelude Therapeutics For: Apr 20
Low
Report
Form 8-K Prelude Therapeutics For: Apr 20
4/15
04:20 pm
prld
Form 3 Prelude Therapeutics For: Apr 15 Filed by: Morris Charles Q
High
Report
Form 3 Prelude Therapeutics For: Apr 15 Filed by: Morris Charles Q
4/15
07:41 am
prld
Form 8-K Prelude Therapeutics For: Apr 15
High
Report
Form 8-K Prelude Therapeutics For: Apr 15
3/19
07:39 pm
prld
Form 3 Prelude Therapeutics For: Mar 05 Filed by: Brusky Sean P.
Medium
Report
Form 3 Prelude Therapeutics For: Mar 05 Filed by: Brusky Sean P.
3/12
04:18 pm
prld
Form 8-K Prelude Therapeutics For: Mar 12
Low
Report
Form 8-K Prelude Therapeutics For: Mar 12
3/12
04:17 pm
prld
Form 424B5 Prelude Therapeutics
Low
Report
Form 424B5 Prelude Therapeutics
3/10
08:25 am
prld
Form 10-K Prelude Therapeutics For: Dec 31
High
Report
Form 10-K Prelude Therapeutics For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: